Sunshine Biopharma, Inc. (SBFMW) Stock Analysis

Sunshine Biopharma, Inc. (SBFMW) Healthcare & Pipeline Overview

Sunshine Biopharma, Inc. is a Canadian pharmaceutical and nutritional supplement company specializing in the research and development of novel anticancer drugs like Adva-27a, effective against multidrug-resistant cancers, and antiviral compounds such as SBFM-PL4. The company also markets a range of scientifically-formulated nutritional supplements.

What Is the Investment Thesis for SBFMW?

Sunshine Biopharma, Inc. presents a research-driven profile centered on its pipeline of novel drug candidates and established nutritional supplement offerings. The primary value drivers stem from the potential advancement and eventual commercialization of Adva-27a, an anticancer compound demonstrating effectiveness against a broad spectrum of cancers, notably multidrug-resistant variants, which represent a significant unmet medical need. The development of SBFM-PL4, an anti-coronavirus treatment, further diversifies its therapeutic focus, bolstered by a licensing agreement with the University of Georgia. Growth catalysts include successful progression of Adva-27a and SBFM-PL4 through preclinical and potential clinical trials, expanding the market reach of its nutritional supplements, and securing future strategic partnerships or financing. However, the company's financial profile, characterized by a negative profit margin of -17.0% and a very small market capitalization of approximately $400,000, indicates a high-risk, high-reward investment scenario. The beta of 0.65 suggests lower volatility relative to the market, but the preclinical stage of its lead compounds and dependency on successful R&D outcomes are critical considerations for potential investors.

Based on FMP financials and quantitative analysis

SBFMW Key Highlights

Market capitalization of approximately $400,000 as of the latest data, indicating a micro-cap company with potential liquidity considerations.

• Reported profit margin of -17.0%, reflecting significant investment in research and development activities for its drug pipeline.
• Gross margin of 32.5% from its operational activities, primarily driven by nutritional supplement sales.
• A workforce of 52 employees, focused on pharmaceutical research, development, and nutritional product marketing.
• Beta of 0.65, suggesting the stock has historically exhibited lower volatility compared to the broader market.

Who Are SBFMW's Competitors?

SBFMW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SBFMW's Key Strengths?

Proprietary drug pipeline includes Adva-27a, effective against multidrug-resistant cancers, addressing a high unmet medical need.

• Development of SBFM-PL4 as an anti-coronavirus treatment diversifies its therapeutic focus.
• Existing revenue stream from the sale of scientifically-formulated nutritional supplements.
• Strategic licensing agreement with the University of Georgia for SBFM-PL4 development.

What Are SBFMW's Weaknesses?

Very small market capitalization of approximately $400,000, indicating potential volatility and liquidity concerns.

• Negative profit margin of -17.0%, reflecting substantial R&D expenses and limited commercial drug revenue.
• Lead drug candidates, Adva-27a and SBFM-PL4, are in preclinical development, implying long timelines and high risk.
• High dependency on successful R&D outcomes and future financing activities to sustain operations.

What Could Drive SBFMW Stock Higher?

SBFMW catalyst: Research and development of Adva-27a continues, targeting a broad spectrum of cancers, including multidrug-resistant forms, which could lead to significant therapeutic breakthroughs.

• Development of SBFM-PL4 as an anti-coronavirus treatment compound is progressing, supported by a licensing agreement with the University of Georgia, addressing a continuous global health need.
• Marketing and development of scientifically-formulated nutritional products, including Essential 9 and Essential Calcium-Vitamin D, provides a current revenue stream and market presence.
• Potential progress in preclinical or clinical trials for Adva-27a or SBFM-PL4 could significantly de-risk the pipeline and attract further investment or partnerships.
• Future financing activities, as indicated by existing AI insights, could provide necessary capital to accelerate drug development and expand operational capabilities.

What Are the Key Risks for SBFMW?

Financial-distress signal — its Altman Z-Score of -27.27 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• The company's very small market capitalization, approximately $400,000, poses potential concerns regarding stock volatility and liquidity for investors.
• A negative profit margin of -17.0% indicates that the company is currently operating at a loss, primarily due to significant R&D expenditures for its drug pipeline.
• High dependency on the successful preclinical and clinical development of its drug candidates, Adva-27a and SBFM-PL4, which are inherently uncertain, lengthy, and costly processes.
• Intense competition within the pharmaceutical industry from larger, more established companies with greater financial and research resources in both oncology and antiviral therapeutic areas.
• Significant regulatory hurdles and the extensive time required for drug approval processes could delay or prevent the commercialization of its pipeline products.

What Are the Growth Opportunities for SBFMW?

• Advancement of Adva-27a through preclinical and clinical trials represents a significant growth opportunity. Adva-27a targets a broad spectrum of cancers, including multidrug-resistant forms, which are notoriously difficult to treat and represent a substantial unmet medical need. The global oncology drug market is projected to reach over $300 billion by 2030, with a strong demand for novel therapies. Successful progression of Adva-27a could unlock access to a high-value market segment, potentially attracting partnerships or substantial investment, with a timeline dependent on regulatory and trial milestones.
• The development and potential commercialization of SBFM-PL4, an anti-coronavirus treatment compound, offers another key growth driver. The ongoing need for effective antiviral therapies, particularly in response to emerging viral threats, ensures a continuous market. The licensing agreement with the University of Georgia provides a collaborative framework for its development. The global antiviral drug market is significant and responsive to public health crises, suggesting a potential for rapid market entry and adoption upon successful development and approval, with a timeline influenced by research progress and regulatory pathways.
• Expansion within the nutritional supplement market provides a more immediate and stable growth avenue. Sunshine Biopharma currently offers products like Essential 9 and Essential Calcium-Vitamin D. The global dietary supplements market is projected to exceed $300 billion by 2028, driven by increasing consumer health awareness. By developing and marketing additional scientifically-formulated nutritional products, the company can leverage existing distribution channels and brand recognition to capture a larger share of this growing market, with ongoing opportunities for product line extensions and geographic expansion.
• Forging additional strategic partnerships and licensing agreements, similar to the one with the University of Georgia for SBFM-PL4, can accelerate drug development and mitigate R&D costs. Such collaborations provide access to external expertise, funding, and broader research capabilities, enhancing the probability of success for its pipeline candidates. The pharmaceutical industry frequently relies on these models to bring novel therapies to market, offering a pathway for Sunshine Biopharma to de-risk its drug development programs and potentially monetize its intellectual property, with opportunities arising as drug candidates demonstrate further promise.
• Addressing high unmet medical needs, particularly in multidrug-resistant cancers, positions Sunshine Biopharma for significant impact and market capture. Adva-27a's demonstrated effectiveness against challenging cancers like pancreatic, breast, and small-cell lung cancer, which often have limited treatment options, highlights this potential. By focusing on areas where existing therapies are insufficient, the company targets patient populations with urgent needs, which can lead to faster regulatory pathways and premium pricing upon approval. This strategic focus aligns with a market segment that values innovation and efficacy highly, offering long-term growth potential as its pipeline matures.

What Are SBFMW's Competitive Advantages?

• Proprietary drug candidates, such as Adva-27a and SBFM-PL4, represent unique intellectual property in oncology and antiviral therapeutics.
• Focus on multidrug-resistant cancers with Adva-27a addresses a critical unmet medical need, offering a differentiated approach in a challenging therapeutic area.
• Strategic licensing agreement with the University of Georgia for SBFM-PL4 provides external validation and collaborative development resources.
• Expertise in developing scientifically-formulated nutritional supplements, complementing its pharmaceutical R&D efforts.

What Does SBFMW Do?

Sunshine Biopharma, Inc., headquartered in Pointe-Claire, Canada, operates as a pharmaceutical and nutritional supplement company with a primary focus on the research and development of innovative anticancer drugs. The company's core pharmaceutical pipeline features Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin. This compound is currently undergoing development to target a broad spectrum of cancers, demonstrating efficacy against leukemia, lymphoma, and tumors affecting the testicular, lung, brain, prostate, bladder, colon, ovarian, and liver. A particularly significant aspect of Adva-27a's profile is its proven effectiveness against various multidrug-resistant cancer cells, including those associated with pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma, addressing a critical unmet medical need in oncology. In addition to its oncology efforts, Sunshine Biopharma is actively developing SBFM-PL4, an anti-coronavirus treatment compound. The company has strategically entered into a licensing agreement with the University of Georgia to advance the development of this lead anti-coronavirus therapeutic. Beyond its pharmaceutical research, Sunshine Biopharma maintains a diversified presence in the health sector through its nutritional supplement division. This segment offers products such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside a continuous effort to develop and market other scientifically-formulated nutritional products. With 52 employees, the company is positioned as an R&D-focused entity within the specialty and generic drug manufacturing industry, aiming to bring novel therapeutic agents and health solutions to market.

What Products and Services Does SBFMW Offer?

• Research and develop innovative anticancer drugs, with a focus on novel compounds.
• Develop Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, for a broad spectrum of cancers.
• Advance Adva-27a specifically for its effectiveness against multidrug-resistant cancer cells.
• Research and develop SBFM-PL4 as an anti-coronavirus treatment compound.
• Engage in licensing agreements, such as with the University of Georgia, to further drug development.
• Manufacture and market a range of scientifically-formulated nutritional supplements.
• Offer specific nutritional products, including the Essential 9 tablet and Essential Calcium-Vitamin D supplement.

How Does SBFMW Make Money?

• Generates revenue through the sale of its scientifically-formulated nutritional supplements, such as Essential 9 and Essential Calcium-Vitamin D.
• Invests significantly in research and development for its pharmaceutical pipeline, including anticancer and antiviral drug candidates, with the aim of future commercialization.
• Utilizes licensing agreements, like the one with the University of Georgia for SBFM-PL4, to collaborate on drug development and potentially generate future royalty or milestone payments.
• Aims to derive future revenue from the successful clinical development, regulatory approval, and commercialization of its proprietary pharmaceutical drugs.

What Industry Does SBFMW Operate In?

Sunshine Biopharma, Inc. operates within the highly dynamic and competitive Drug Manufacturers - Specialty & Generic industry, a segment of the broader Healthcare sector. This industry is characterized by continuous innovation, significant R&D investment, and stringent regulatory pathways. The company's focus on novel anticancer drugs, particularly those effective against multidrug-resistant cancers, positions it within a high-growth and high-need segment of the pharmaceutical market, where global spending on oncology therapeutics continues to expand. Similarly, its development of an anti-coronavirus compound addresses an ongoing public health priority. While the industry is dominated by large pharmaceutical players, smaller biotech firms like Sunshine Biopharma often carve out niches by targeting specific disease mechanisms or unmet medical needs. The company's additional segment in nutritional supplements places it in a growing consumer health market, offering a diversified revenue stream alongside its long-term pharmaceutical ambitions.

Who Are SBFMW's Key Customers?

• Consumers seeking health and wellness products, who purchase its range of nutritional supplements.
• Potentially, healthcare providers and patients, upon the successful development and regulatory approval of its pharmaceutical drug candidates.
• Academic institutions and other pharmaceutical companies, through collaborative research and licensing agreements for its drug compounds.

Wall Street analysts project Sunshine Biopharma, Inc. revenue of about $35.4M for fiscal 2026, with EPS near $-6.30.

Sunshine Biopharma, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -27.27 places it in the distress zone, a signal of elevated financial risk.

Company Profile

Sunshine Biopharma, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Fort Lauderdale, US. The company is led by CEO Steve N. Slilaty. SBFMW has traded publicly since 2022.

SBFMW Financials

SBFMW Latest News

No recent news available for SBFMW.

SBFMW Analyst Consensus

SBFMW MoonshotScore

What Investors Ask About Sunshine Biopharma, Inc. (SBFMW) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources